The company aims to release an initial tissue-based prognostic this year, with a less-invasive sponge-sampling version for screening high-risk individuals to follow in 2023.
Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test
The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
The JHU technology leverages an epigenetic biomarker panel and a sponge-on-a-string collection device, as well as a PCR-based method, to detect Barrett's esophagus.
Noninvasive Prostate Cancer MDx Test Enters Validation Phase After Initial Results Published in JCO
The qPCR assay measures methylation of six genes and could help doctors identify aggressive vs indolent prostate cancer more accurately than PSA.
Epigenomics Pushes New Promotion Efforts for ProColon Test as Other Assays in Pipeline Advance
The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.